← Back to blog

Related Party Disclosure Analysis: A Forensic Method for SEC Filings

November 13, 2026
Related Party Disclosure Analysis: A Forensic Method for SEC Filings

Related party disclosure analysis is the systematic comparison of what a registrant reports about insiders and affiliates across the financial statement footnotes, the proxy statement and the risk and business sections of its filings, tested against what the transactions imply for cost, margin and governance. The method is only as strong as its consistency: the same definitions, the same extraction fields and the same thresholds applied to every issuer. Lacuna Index applies one standardized, public-records-only process across all covered companies and publishes governance logs for its scoring, so a related party finding can be traced back to the filing line that produced it.

Lacunaindex
lacunaindex.com
Compare Corporate Claims With Delivery
Lacuna Index analyzes public disclosures to assess how companies deliver on their claims, supporting evidence-based governance and investment decisions.
Visit

TL;DR

  • Two definitions govern U.S. disclosure: ASC 850 for the financial statements and Item 404 of Regulation S-K for the proxy and Part III. They overlap but are not interchangeable.
  • Read the footnote, Item 13 or its proxy cross-reference, the business description and the risk factors together. Inconsistency between them is the first signal.
  • Quantify supplier concentration as a share of purchases or cost of goods sold, then ask whether the supplier is a related party and whether arm's-length terms are substantiated.
  • Concentration plus improving margins plus vague wording is the pattern that warrants escalation to a full forensic read.

Table of Contents

1. Two definitions, two disclosure regimes

Analysis starts by separating the accounting definition from the securities-law definition, because a transaction can sit in one and not the other.

ASC 850. Under ASC 850-10-20, related parties include affiliates, equity-method investees, trusts for the benefit of employees, principal owners and management with their immediate families, and any other party where one side can control or significantly influence the other to the point that a transacting party might be prevented from fully pursuing its own separate interests, as summarized in PwC's U.S. accounting guide. The same guide notes that Regulation S-X refers back to the GAAP definition for financial statements, while other SEC rules, such as Item 404, carry definitions that apply only to those rules.

Item 404. A "related person" for Item 404 includes any director or executive officer, any director nominee, any immediate family member of either (including anyone sharing their household), any person known to own more than five percent of a class of voting securities, and that holder's immediate family, according to the Regulation S-K instructions reproduced in the PLI SEC Reporting Handbook. The dollar threshold for disclosure of a related person transaction was raised from $60,000 to $120,000, and Item 404(b) requires disclosure of whether the company has policies for reviewing, approving or ratifying such transactions and whether they are written.

The practical difference is scope. Crowe's 2023 analysis explains that ASC 850 governs disclosure inside the financial statements, while the SEC requires related party disclosure incremental to GAAP, both inside and outside the statements. Banks add a further layer: Regulation S-X Rule 9-03.7(e)(4) supplies a more prescriptive definition with bright-line thresholds for certain balance sheet disclosures, and Regulation O limits and requires disclosure of loans to insiders of a financial institution.

The SEC also expects registrants to consider disclosing relationships that fall outside the formal definition when they enable terms not available on an arm's-length basis, such as continued business with former management, per the same PwC guide. For an analyst, this means a clean footnote does not prove the absence of non-arm's-length dealing.

1. Two definitions, two disclosure regimes

2. What ASC 850 requires a company to say

ASC 850-10-50-1, as excerpted by PwC, sets the minimum content of the footnote. An extraction template should carry one field for each element:

Required elementExtraction fieldAnalytical question
Nature of the relationshipCounterparty, ownership or control linkIs the party named, or described only generically?
Description of transactions, including those with nominal or no amountsTransaction type, periodAre no-charge arrangements (shared services, guarantees) captured?
Dollar amounts for each income statement periodAmount per yearDoes the trend track business activity?
Effect of any change in method of establishing termsPricing method changeDid terms move after a margin or covenant event?
Amounts due from or to related parties at each balance sheet date, with settlement termsReceivable, payable, termsAre balances growing faster than volume?

One rule deserves particular attention. Under ASC 850-10-50-5, a company may state that a transaction was at arm's length only when it can substantiate the representation. A related party loan, for instance, may be called arm's length only if its terms equal those an unrelated lender would have given, per PwC's discussion of the disclosure rules. Boilerplate claiming "terms comparable to unrelated parties" with no description of how that was determined is a disclosure-quality finding in its own right.

No single section is complete. A forensic read triangulates at least five locations.

  1. Financial statement footnotes. The dedicated related party note is the primary source for amounts and balances. Note numbering varies by issuer, so locate it by title rather than position. ASC 850 also requires related party receivables and payables to be shown separately on the face of the balance sheet, which gives a quick cross-check against the note.
  2. Form 10-K Item 13 (Part III). This item addresses certain relationships and related transactions and director independence. Registrants commonly incorporate it by reference from the proxy statement, so the analysis must follow the cross-reference to the definitive proxy. The related person section there is where Item 404 narrative, including the approval policy, sits. Further proxy patterns are covered in six forensic proxy statement red flags.
  3. Item 101 business description and Item 105 risk factors. Dependence on a single or limited set of suppliers appears here, and a related party supplier may be described without any reference to its status.
  4. MD&A (Item 303). Cost structure, sourcing and known trends. The comparison between MD&A language and the footnote is the core of a narrative-versus-delivery test, laid out in the MD&A forensic workflow.
  5. Ownership, consolidation and commitments disclosures. Equity-method investments, variable interest entities and guarantees can reveal that a counterparty is an affiliate. Obligations that never reach the balance sheet are treated in the guide to off-balance-sheet commitments.

The PCAOB's auditing standard offers a useful checklist of where undisclosed relationships surface. AS 2410 lists SEC filings, company website disclosures, tax filings, professional-advisor invoices, conflicts-of-interest statements, shareholder registers, significant unusual or renegotiated contracts, whistleblower-program records, executive expense reimbursements and organizational charts. Outside analysts cannot see most of these, but the public subset (filings, website, proxy, subsidiaries lists and exhibits, particularly material contracts filed under Item 601) is enough to build a counterparty map.

Supplier concentration disclosure and related party disclosure meet when a major supplier is an insider-linked entity. Each regime answers a different question: concentration rules ask how vulnerable the company is, and related party rules ask on what terms and with whom it deals.

A company's sourcing dependence can surface in several places: ASC 275 notes where a concentration creates vulnerability to a reasonably possible near-term severe impact, Item 101(c) for dependence on single or limited suppliers, Item 105 risk factors, and Item 303 where a known trend or uncertainty is reasonably likely to have a material effect. ASC 275 sets no bright-line percentage. Practitioner commentary treats purchases above 10% from one source as routinely disclosed and above 25% as almost always disclosed, as one SEC disclosure guide puts it, which makes those levels sensible screening triggers rather than rules.

Two filings show what the data looks like in practice:

  • One issuer's interim filing reports that products from a single privately owned manufacturer under a long-term supply agreement accounted for about 22% of gross revenues in the six months ended September 30, 2025 and 23% a year earlier. It also notes that the company represented a significant portion of that supplier's own gross revenues, which is the mutual-dependency point. Long-term contracts with 17 manufacturers covered about 57% of gross sales.
  • Another registrant disclosed that a related party supplier represented approximately 45% of total purchases in the fiscal year ended May 3, 2025, that the relationship is disclosed under ASC 850, and that terms are evaluated for comparability with unrelated parties. It added that a disruption at the supplier could materially and adversely affect operations and results.

The second example is the pattern this article is about. A 45% share is a concentration disclosure, an ASC 850 disclosure and a risk factor at once, and each must reconcile with the others. The analyst's task is to test the sentence "terms are comparable" against the evidence on offer: price benchmarks, contract terms, board approval and auditor commentary.

Companies are also not required to name every supplier. The SEC's position, as reflected in comment letter responses, is that a registrant must describe and quantify a concentration but may withhold the supplier's name where naming would expose competitively sensitive sourcing, per the same disclosure guide. Competitive sensitivity does not excuse omitting quantification. A concentration described only in adjectives is therefore a gap.

For customer-side symmetry, the same logic is applied in the customer concentration disclosure model notes.

5. A repeatable analytical sequence

The sequence below converts the disclosure rules into a workflow. Each step produces a number or a yes/no finding that can be logged.

  1. Build the counterparty list. Pull every named related person and entity from the footnote, Item 13 and the proxy, then add subsidiaries, equity-method investees and director affiliations from exhibits and director biographies.
  2. Size each relationship. Express related party purchases as a percentage of total purchases, cost of goods sold and operating expenses. Express receivables, payables, prepayments and advances against the matching balance sheet totals.
  3. Check trend against activity. Balances or purchase shares that rise faster than revenue or volume need an explanation in MD&A. Rising concentration alongside improving reported margins is the pattern that warrants most skepticism, since the margin may depend on prices not set in a competitive market.
  4. Test the arm's-length statement. Is the claim made, and is any basis given? Under ASC 850-10-50-5 the claim requires substantiation.
  5. Test the approval path. Item 404(b) requires the policy disclosure. For NYSE-listed registrants, Section 314.00 of the Listed Company Manual, as amended, requires the audit committee or another independent body to review in advance all related party transactions disclosable under Item 404, irrespective of value, and to prohibit any found inconsistent with the interests of the company and its shareholders, according to the Harvard Law School Forum on Corporate Governance. Look for evidence that the review occurred.
  6. Cross-read the narrative. Does the business section, the risk factor and the earnings call describe the same dependence the footnote quantifies?
  7. Check the auditor layer. AS 2410 states that the auditor's objective is evidence on whether related parties and their transactions have been properly identified, accounted for and disclosed. For each disclosable or significant-risk transaction, the auditor reads the underlying documents, evaluates business purpose, determines whether approval followed company policy and whether exceptions were granted, and evaluates the related party's financial capability regarding uncollected balances, loan commitments, supply arrangements and guarantees. Check whether the auditor's report references related party transactions as a critical audit matter.
  8. Assess operational exposure. Beyond the share of spend, record contract termination rights, switching cost and time, geography, the supplier's financial condition and whether the dependence is mutual. A supplier at a small share of spend can still be the only source of something essential, so segment by category as well as in total.

6. Red flags that warrant escalation

Item 404 exists to give investors the information needed to judge whether management is putting shareholder interests first or the board is letting insiders extract value through favorable transactions. The flags below are the observable signs that this might be happening.

FlagWhere it appearsWhy it matters
Counterparty described generically ("an affiliate of a director")Footnote, proxyPrevents independent verification of terms
Arm's-length language with no stated basisFootnoteASC 850-10-50-5 requires substantiation
Purchase share rising year over yearFootnote against MD&AReported costs depend more on non-market pricing
Related party payables or advances outpacing activityBalance sheetMay signal financing of an affiliate or cash movement off the books
Footnote and proxy list different transactionsNotes versus Item 13Different definitions explain some gaps, but not unexplained ones
Amended or renegotiated terms after a period of weak resultsFootnote, exhibitsASC 850 requires disclosure of changes in the method of establishing terms
Risk factor names a supplier dependence that the footnote does not quantifyItem 105 versus notesConcentration description without quantification
Material related party contract absent from exhibitsExhibit indexPossible incomplete disclosure

Governance signals sit alongside these. Compare the pattern with governance red flags in public disclosures and with indicators of shareholder vote manipulation, because related party dealings often coincide with governance structures that weaken independent oversight.

Consider the registrant that reported approximately 45% of purchases from a related party supplier. A forensic read would proceed as follows, using only the public record.

Size. At 45% of purchases, the supplier exceeds the 25% level at which concentration is almost always disclosed, and the exposure sits in cost of goods sold, so any pricing latitude flows directly into gross margin.

Terms. The registrant states it evaluates transactions to ensure terms are comparable with unrelated parties. The analyst records whether the filing describes the method, whether a price benchmark is given and whether an independent committee approved the arrangement.

Consistency. The disclosed risk of a supply disruption is the same dependence the footnote quantifies. The question is whether MD&A explains gross margin movement in terms of this supplier's pricing, volume or mix.

Outcome. Each answer becomes a logged finding with its filing reference. A company that quantifies the share, names the relationship, explains the business rationale and shows independent approval scores differently from one that does only the first of these. Neither finding implies misconduct. The finding is a measured gap, or its absence, between what is claimed and what is evidenced.

Four checks for a related-party supplier

8. Where the Lacuna Index approach fits

Manual review of one issuer is tractable. Reviewing a sector with consistent standards is not, because each analyst weights these items differently. Lacuna Index quantifies the gap between corporate narrative claims and delivery using public records only, with methodology standardized across covered companies and governance logs published for all scoring, which is what makes cross-issuer comparison and audit tracing possible. The methodology walkthrough sets out the process, and the free sector benchmarks show how sectors compare on execution.

Subscribers get per-company forensic reports with execution and narrative scores, and the Cohort Pulse and Sector Sweep plans are described on the pricing page. Per-company analysis is available through the benchmarks section.

Lacunaindex

9. Perspective

Related party disclosure is where the distance between narrative and delivery is easiest to measure and easiest to miss. The numbers are in the footnote, the story is in the business description, and the approval record is in the proxy. Each is accurate in isolation. The gap shows only when the three are read against one another with the same rules for every issuer.

That is why we built Lacuna Index on public records alone and on a single methodology across all covered companies. A related party finding is only worth acting on if another analyst can reproduce it from the filing. Our governance logs for scoring and audit-traceable evidence exist so that a reader can follow a conclusion back to the sentence in the filing that supports it.

For institutional investors, proxy advisors and journalists, the practical benefit is comparability: a supplier concentration or an arm's-length claim at one issuer can be read against its sector rather than in isolation, and the sector benchmarks are free to start from.

Glen

FAQ

Is the Item 404 definition the same as the ASC 850 definition?

No. ASC 850 defines related parties for financial statement purposes, and Regulation S-X points to that definition. Item 404 has its own definition of a related person that applies only to that rule. A transaction can therefore appear in the proxy and not the footnote, or the reverse, and the difference should be reconciled rather than assumed away.

The ASC 850 footnote requires the nature of the relationship and the transaction amounts. For supplier concentration generally, the SEC's position as reflected in comment letter responses is that a company must describe and quantify the concentration but may not need to name a supplier where that would expose competitively sensitive sourcing. Quantification cannot be omitted on those grounds.

Which percentage of purchases should trigger a closer look?

No rule sets a bright line under ASC 275. Practitioner guidance treats more than 10% from one source as routinely disclosed and more than 25% as almost always disclosed, so those levels work as screening points. A supplier that is a related party deserves review at a lower share, since the pricing is not necessarily set in a competitive market.

Start with the related party footnote for amounts and balances, then follow Item 13 to the proxy statement, where the Item 404 narrative and approval policy usually appear. Then compare against the business description, risk factors and MD&A for dependence the footnote does not mention.

Sources